Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03990051 · ClinicalTrials.gov registry record · Phase 2
Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
A Phase 2 study of Chronic Ocular Graft-versus-host Disease, sponsored by Glia.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03990051 is a Phase 2 study of Chronic Ocular Graft-versus-host Disease that has completed, run by Glia. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03990051, a Phase 2 study of Chronic Ocular Graft-versus-host Disease, has completed, sponsored by Glia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
Conditions Studied
Interventions
- DRUG Placebo topical gel
- DRUG Pro-ocular™ topical gel
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Longwood - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2021-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03990051
The ClinicalTrials.gov registry entry for NCT03990051 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glia, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Ocular Graft-versus-host Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo topical gel is the first listed.
NCT03990051 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03990051 about?
NCT03990051 is a clinical study titled "Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.". To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
What is the current status of trial NCT03990051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2019-10-17. Estimated completion is 2021-11-19.
What conditions does trial NCT03990051 study?
This clinical trial studies the following conditions: Chronic Ocular Graft-versus-host Disease.
What interventions are being tested in trial NCT03990051?
The interventions under investigation include: Placebo topical gel (DRUG), Pro-ocular™ topical gel (DRUG).
Who is sponsoring clinical trial NCT03990051?
This trial is sponsored by Glia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03990051 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Ocular Graft-versus-host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.